Navigation Links
InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF
Date:7/7/2011

BRISBANE, Calif., July 7, 2011 /PRNewswire/ -- InterMune (NASDAQ: ITMN) today announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis (IPF).  ASCEND is a multinational, randomized, double-blind, placebo controlled Phase 3 trial designed to evaluate the safety and efficacy of Esbriet® (pirfenidone) in IPF patients with mild to moderate impairment in lung function.  The primary endpoint is lung function, as measured by change in forced vital capacity (FVC) from baseline to Week 52.  The trial will enroll a total of approximately 500 patients who will be randomly assigned 1 to 1 to receive oral pirfenidone (2403 mg/day) or placebo.  Patients will be enrolled at centers in the United States, Mexico, South America, Australia and New Zealand.  

Steve Porter, M.D., Ph.D., Chief Medical Officer of InterMune, said, "We are very pleased to report enrollment of the first patient in ASCEND.  This study represents our continued commitment to making Esbriet available for the more than 100,000 IPF patients in the United States who are afflicted with IPF but currently have no FDA-approved therapies available to them."  

ASCEND Phase 3 Trial

InterMune's new Phase 3 study of pirfenidone is named ASCEND (Assessment of Pirfenidone to Confirm Efficacy and Safety in IPF).  ASCEND will add to pirfenidone's body of clinical evidence and support a future submission for FDA approval.

InterMune expects the trial to be fully enrolled by the first half of 2012, and that results from the study will be available in mid-2013.  InterMune anticipates a New Drug Application (NDA) resubmission for pirfenidone in the second half of 2013 and an FDA action in the first half of 2014.  

Relative to InterMune's previous studies o
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
5. InterMune to Release Third Quarter 2008 Financial Results on November 6
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune to Present at J.P. Morgan Healthcare Conference
9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... AudioNotch is the internet's leading provider ... treatment of tinnitus. Patients listen to sound therapy that ... period of weeks to months, their tinnitus volume decreases. , ... Notched Music and Notched White Noise. Now, AudioNotch is pleased ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... 14, 2014 The largest international professional organization ... and therapeutic derivatives thereof has endorsed an educational ... about the challenges of adulterated herb and botanical ... The Society for Medicinal Plant and ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... (May 4, 2010) Endoscopic radiofrequency ablation is an ... offers a fast and effective way to detect inflammatory ... replace gastrointestinal tissue that is removed, and researchers find ... the bile duct) is more precise than surgery with ...
... and EMERYVILLE, Calif. , May 4 S*BIO Pte ... expansion of their development collaboration and option and license commercialization agreement for ... and ONX 0805, respectively. The expanded agreement builds upon the development and ... , , , ...
... ... leak testing procedures through the roll-out of a global Summer seminar and exhibition ... current packaging test methods within the pharmaceutical industry. , ... Belfast (Vocus) May 5, 2010 -- Package integrity ...
Cached Biology Technology:Latest breakthroughs in technology expand options for diagnosing and treating disease 2Latest breakthroughs in technology expand options for diagnosing and treating disease 3Latest breakthroughs in technology expand options for diagnosing and treating disease 4Latest breakthroughs in technology expand options for diagnosing and treating disease 5Latest breakthroughs in technology expand options for diagnosing and treating disease 6Latest breakthroughs in technology expand options for diagnosing and treating disease 7Latest breakthroughs in technology expand options for diagnosing and treating disease 8Latest breakthroughs in technology expand options for diagnosing and treating disease 9Latest breakthroughs in technology expand options for diagnosing and treating disease 10Latest breakthroughs in technology expand options for diagnosing and treating disease 11S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 2S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 3S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 4S*BIO and Onyx Pharmaceuticals Announce Expanded Development Collaboration for JAK2 Inhibitors 5Pharmaceutical Leak Testing Practices challenged by SEPHA 2Pharmaceutical Leak Testing Practices challenged by SEPHA 3
(Date:4/17/2014)... the Australian National University (ANU), have developed a ... temperature variability over the past 5.3 million years., ... climate surrounding ice ages over the past two ... between carbon dioxide levels, global temperatures and sea ... Southampton (UoS) and the National Oceanography Centre (NOC) ...
(Date:4/16/2014)... artisanal green sea turtle fishery has uncovered a stark ... what may have become an unsustainable take, according to ... of Florida. , During the research period, conservation scientists ... between 1991 and 2011, with catch rates peaking in ...
(Date:4/16/2014)... of a leaf looks like one seamless surface; however, ... of a patchwork of cells in a variety of ... take on their own unique forms, Caltech biologist Elliot ... pinpoint the shape-controlling factors in pavement cells, which are ...
Breaking Biology News(10 mins):Ancient sea-levels give new clues on ice ages 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 3For cells, internal stress leads to unique shapes 2
... deepest oceans of the world would appear to be shark ... team of researchers, led by the University of Aberdeen, reveal ... 3,000 metres. , Sharks occur throughout the world's oceans and ... the abyss and beyond throughout the largest environment on the ...
... any other organism, an influenza virus's success in life is ... on genes from one generation to the next. , But ... of flu viruses, how the microbe organizes its genetic contents ... mystery of biology. , Now, with the help of a ...
... bad. Mothers and doctors, not to mention the cleaning ... Stanford University School of Medicine microbiologist is raising the ... benefits. , Stanley Falkow, PhD, the Robert W. and ... his thoughts on this topic in an essay in ...
Cached Biology News:Oceans are 70 percent shark free 2UW scientists unravel critical genetic puzzle for flu virus replication 2UW scientists unravel critical genetic puzzle for flu virus replication 3Scientists look to the Bahamas as a model for coral reef conservation 2Scientists look to the Bahamas as a model for coral reef conservation 3